CA 19–9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer (Q58230752)

0 references

Laura Visa

0 references

Carles Conill

0 references

Salvador Navarro

0 references

Jose M. Escudero

0 references

Jose M. Auge

0 references

Xavier Filella

0 references

Miguel A. Lopez-Boado

0 references

Joana Ferrer

0 references

Laureano Fernandez-Cruz

0 references

Rafael Molina

Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas

0 references

publication date

29 December 2011

0 references

0 references

0 references

0 references

799-807

0 references

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

21 January 2018

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

Early detection of pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

An evidence-based approach to the diagnosis and staging of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

Utility of tumor markers in determining resectability of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

A new cause for CA19.9 elevation: heavy tea consumption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

Comparative study of CA242 and CA19-9 in chronic pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

Surrogate markers of resectability in patients undergoing exploration of potentially resectable pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

Serum tumor markers and molecular biological diagnosis in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0297-8

21 January 2018

1 reference

12 December 2020

Serum CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinoma

1 reference

12 December 2020

Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas.

1 reference

12 December 2020

Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma

1 reference

12 December 2020

Serum levels of CA19-9 in patients with nonmalignant respiratory diseases

1 reference

12 December 2020

A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve

1 reference

12 December 2020

Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer

1 reference

12 December 2020

Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.

1 reference

12 December 2020

TAG-72, CA 19.9 and CEA as tumor markers in gastric cancer

1 reference

12 December 2020

The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma

1 reference

12 December 2020

Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma

1 reference

12 December 2020

Primary hydatid cyst of the breast with elevated CA 19-9 level

1 reference

12 December 2020

Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9

1 reference

12 December 2020

The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer

1 reference

12 December 2020

Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer

1 reference

12 December 2020

A Case of Common Bile Duct Stone with Cholangitis Presenting an Extraordinarily High Serum CA19-9 Value

1 reference

12 December 2020

Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease

1 reference

12 December 2020

CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice

1 reference

12 December 2020

Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE

1 reference

12 December 2020

Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer

1 reference

12 December 2020

Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head

1 reference

12 December 2020

Clinicopathological aspects of small pancreatic cancer

1 reference

12 December 2020

A Prospective Study of Tumor Markers CA 125 and CA 19.9 in Patients with Epithelial Ovarian Carcinomas

1 reference

12 December 2020

Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature.

1 reference

12 December 2020

Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer

1 reference

12 December 2020

Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9

1 reference

12 December 2020

Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access GI Monitor assay on the UniCel Dxl 800 Immunoassay System

1 reference

12 December 2020

Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes

1 reference

12 December 2020

The clinical utility of the CA 19-9 tumor-associated antigen.

1 reference

12 December 2020

[CA19-9 has no value as a tumor marker in obstructive jaundice]

1 reference

12 December 2020